Guangxi Wuzhou Zhongheng Group Co Ltd (600252) - Total Liabilities
Based on the latest financial reports, Guangxi Wuzhou Zhongheng Group Co Ltd (600252) has total liabilities worth CN¥3.65 Billion CNY (≈ $534.68 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore long-term investment intensity of Guangxi Wuzhou Zhongheng Group Co Ltd to see how much of total assets are deployed in long-term investments.
Guangxi Wuzhou Zhongheng Group Co Ltd - Total Liabilities Trend (1997–2025)
This chart illustrates how Guangxi Wuzhou Zhongheng Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Guangxi Wuzhou Zhongheng Group Co Ltd's balance sheet.
Guangxi Wuzhou Zhongheng Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guangxi Wuzhou Zhongheng Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trupanion Inc
NASDAQ:TRUP
|
USA | $521.14 Million |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
China | CN¥1.23 Billion |
|
Corporación Interamericana de Entretenimiento S.A.B. de C.V
MX:CIEB
|
Mexico | MX$6.75 Billion |
|
Procept Biorobotics Corp
NASDAQ:PRCT
|
USA | $131.26 Million |
|
Rackspace Technology Inc
NASDAQ:RXT
|
USA | $3.98 Billion |
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
Taiwan | NT$5.07 Billion |
|
Idorsia Ltd
SW:IDIA
|
Switzerland | CHF1.66 Billion |
|
Vitec Software Group AB (publ)
ST:VIT-B
|
Sweden | Skr6.50 Billion |
Liability Composition Analysis (1997–2025)
This chart breaks down Guangxi Wuzhou Zhongheng Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 600252 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guangxi Wuzhou Zhongheng Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guangxi Wuzhou Zhongheng Group Co Ltd (1997–2025)
The table below shows the annual total liabilities of Guangxi Wuzhou Zhongheng Group Co Ltd from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥3.32 Billion ≈ $486.28 Million |
-4.07% |
| 2024-12-31 | CN¥3.46 Billion ≈ $506.93 Million |
+2.22% |
| 2023-12-31 | CN¥3.39 Billion ≈ $495.94 Million |
-2.12% |
| 2022-12-31 | CN¥3.46 Billion ≈ $506.67 Million |
+8.20% |
| 2021-12-31 | CN¥3.20 Billion ≈ $468.25 Million |
-14.60% |
| 2020-12-31 | CN¥3.75 Billion ≈ $548.28 Million |
+160.63% |
| 2019-12-31 | CN¥1.44 Billion ≈ $210.37 Million |
+9.78% |
| 2018-12-31 | CN¥1.31 Billion ≈ $191.63 Million |
+3.37% |
| 2017-12-31 | CN¥1.27 Billion ≈ $185.38 Million |
+8.84% |
| 2016-12-31 | CN¥1.16 Billion ≈ $170.33 Million |
-0.96% |
| 2015-12-31 | CN¥1.18 Billion ≈ $171.99 Million |
-44.25% |
| 2014-12-31 | CN¥2.11 Billion ≈ $308.52 Million |
-10.99% |
| 2013-12-31 | CN¥2.37 Billion ≈ $346.61 Million |
+52.31% |
| 2012-12-31 | CN¥1.56 Billion ≈ $227.56 Million |
-17.88% |
| 2011-12-31 | CN¥1.89 Billion ≈ $277.10 Million |
+16.11% |
| 2010-12-31 | CN¥1.63 Billion ≈ $238.65 Million |
+75.81% |
| 2009-12-31 | CN¥927.63 Million ≈ $135.74 Million |
+55.56% |
| 2008-12-31 | CN¥596.33 Million ≈ $87.26 Million |
-16.84% |
| 2007-12-31 | CN¥717.08 Million ≈ $104.93 Million |
+1.82% |
| 2006-12-31 | CN¥704.26 Million ≈ $103.06 Million |
-42.62% |
| 2005-12-31 | CN¥1.23 Billion ≈ $179.60 Million |
-5.51% |
| 2004-12-31 | CN¥1.30 Billion ≈ $190.08 Million |
+98.17% |
| 2003-12-31 | CN¥655.48 Million ≈ $95.92 Million |
+84.24% |
| 2002-12-31 | CN¥355.77 Million ≈ $52.06 Million |
+23.98% |
| 2001-12-31 | CN¥286.96 Million ≈ $41.99 Million |
+37.49% |
| 2000-12-31 | CN¥208.72 Million ≈ $30.54 Million |
+15.56% |
| 1999-12-31 | CN¥180.62 Million ≈ $26.43 Million |
-5.90% |
| 1998-12-31 | CN¥191.95 Million ≈ $28.09 Million |
+2.51% |
| 1997-12-31 | CN¥187.24 Million ≈ $27.40 Million |
-- |
About Guangxi Wuzhou Zhongheng Group Co Ltd
Guangxi Wuzhou Zhongheng Group Co., Ltd, together with its subsidiaries, researches, develops, manufactures, and sells pharmaceuticals in China. The company offers traditional Chinese medicine, including Xueshuantong injection, Zhonghua Dieda Wan for traumatic injuries, Fuyanjing capsules, JieShiTong tablets, snake gall and fritillaria liquid, Kunyuean granules, and compound clam oral liquid for … Read more